189 related articles for article (PubMed ID: 34835449)
1. Mt10-CVB3 Vaccine Virus Protects against CVB4 Infection by Inducing Cross-Reactive, Antigen-Specific Immune Responses.
Lasrado N; Arumugam R; Rasquinha MT; Sur M; Steffen D; Reddy J
Microorganisms; 2021 Nov; 9(11):. PubMed ID: 34835449
[TBL] [Abstract][Full Text] [Related]
2. A Monovalent Mt10-CVB3 Vaccine Prevents CVB4-Accelerated Type 1 Diabetes in NOD Mice.
Rasquinha MT; Lasrado N; Sur M; Mone K; Qiu H; Riethoven JJ; Sobel RA; Reddy J
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679922
[TBL] [Abstract][Full Text] [Related]
3. Mt10 Vaccine Protects Diversity Outbred Mice from CVB3 Infection by Producing Virus-Specific Neutralizing Antibodies and Diverse Antibody Isotypes.
Rasquinha MT; Mone K; Sur M; Lasrado N; Massilamany C; Kachman SD; Steffen D; Reddy J
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543901
[TBL] [Abstract][Full Text] [Related]
4. Attenuated strain of CVB3 with a mutation in the CAR-interacting region protects against both myocarditis and pancreatitis.
Lasrado N; Gangaplara A; Massilamany C; Arumugam R; Shelbourn A; Rasquinha MT; Basavalingappa RH; Delhon G; Xiang SH; Pattnaik AK; Steffen D; Reddy J
Sci Rep; 2021 Jun; 11(1):12432. PubMed ID: 34127684
[TBL] [Abstract][Full Text] [Related]
5. Identification of Immunogenic Epitopes That Permit the Detection of Antigen-Specific T Cell Responses in Multiple Serotypes of Group B Coxsackievirus Infections.
Lasrado N; Gangaplara A; Arumugam R; Massilamany C; Pokal S; Zhou Y; Xiang SH; Steffen D; Reddy J
Viruses; 2020 Mar; 12(3):. PubMed ID: 32245257
[TBL] [Abstract][Full Text] [Related]
6. Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.
Reimann BY; Zell R; Kandolf R
J Virol; 1991 Jul; 65(7):3475-80. PubMed ID: 1645779
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection.
Jrad-Battikh N; Souii A; Oueslati L; Aouni M; Hober D; Gharbi J; Ben M'hadheb-Gharbi M
Curr Microbiol; 2014 Apr; 68(4):503-9. PubMed ID: 24322405
[TBL] [Abstract][Full Text] [Related]
8. Multiple subtypes of coxsackievirus group B can cause congenital heart disease.
Sharma V; Goessling LS; Brar AK; Eghtesady P
Birth Defects Res; 2023 Jan; 115(2):171-178. PubMed ID: 36094067
[TBL] [Abstract][Full Text] [Related]
9. Viral Protein VP1 Virus-like Particles (VLP) of CVB4 Induces Protective Immunity against Lethal Challenges with Diabetogenic E2 and Wild Type JBV Strains in Mice Model.
Gharbi J; Hadj Hassine I; Hassine M; Al-Malki M; Al-Yami A; Al-Bachir A; Ben M'hadheb M
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112858
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles.
Wang T; Wang C; Pang L; Zhang Y; Wang S; Liang X; Huang Z
Emerg Microbes Infect; 2024 Dec; 13(1):2337665. PubMed ID: 38551145
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
12. Vaccines against Group B Coxsackieviruses and Their Importance.
Mone K; Lasrado N; Sur M; Reddy J
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851152
[TBL] [Abstract][Full Text] [Related]
13. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.
Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D
J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324
[TBL] [Abstract][Full Text] [Related]
14. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.
Gu R; Shampang A; Nashar T; Patil M; Fuller DH; Ramsingh AI
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824074
[TBL] [Abstract][Full Text] [Related]
15. Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice.
Tracy S; Höfling K; Pirruccello S; Lane PH; Reyna SM; Gauntt CJ
J Med Virol; 2000 Sep; 62(1):70-81. PubMed ID: 10935991
[TBL] [Abstract][Full Text] [Related]
16. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route.
Qi X; Lu Q; Hu J; Xiong S
Microb Cell Fact; 2019 Apr; 18(1):66. PubMed ID: 30947747
[TBL] [Abstract][Full Text] [Related]
18. M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine.
Ye T; Yue Y; Fan X; Dong C; Xu W; Xiong S
Vaccine; 2014 Jul; 32(35):4457-4465. PubMed ID: 24958702
[TBL] [Abstract][Full Text] [Related]
19. Possible Association of Pulmonary Atresia with In-Utero Coxsackievirus B Exposure.
Carvajal HG; Sharma V; Goessling LS; Merritt TC; Brar AK; Eghtesady P
Pediatr Cardiol; 2022 Jun; 43(5):960-968. PubMed ID: 35022808
[TBL] [Abstract][Full Text] [Related]
20. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
Gauntt CJ; Paque RE; Trousdale MD; Gudvangen RJ; Barr DT; Lipotich GJ; Nealon TJ; Duffey PS
Infect Immun; 1983 Feb; 39(2):851-64. PubMed ID: 6299950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
